CODEXIS, INC.
No enriched coverage for $CDXS in the last 7 days.
No SEC Form 4 filings for $CDXS in the last 30 days.
See all $CDXS insider activity →U.S. stocks were mixed mid-session. Verizon (NYSE:VZ) reported Q2 adjusted EPS of $1.30 vs $1.27 consensus, with revenue of $34.25B missing the $35.11B estimate. GAAP EPS fell to 92 cents. Verizon raised full-year adjusted EPS guidance to $4.99-$5.04. Oil fell 4.3% to $88.26.
CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,
CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001200375 0001200375 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
Recent CDXS coverage spans financial news, earnings and corporate actions.
U.S. stocks were mixed mid-session. Verizon (NYSE:VZ) reported Q2 adjusted EPS of $1.30 vs $1.27 consensus, with revenue of $34.25B missing the $35.11B estimate. GAAP EPS fell to 92 cents. Verizon raised full-year adjusted EPS guidance to $4.99-$5.04. Oil fell 4.3% to $88.26.
Preliminary revenue and liquidity estimates can drive near-term repricing ahead of the final quarterly results.
Routine shareholder-meeting outcomes; limited direct signal for near-term fundamentals beyond governance housekeeping.
Analysts have lowered their price target for Codexis, Inc. (CDXS) by 7.1% to US$6.58 following quarterly results showing strong revenue but ongoing profitability concerns.
The announcement indicates Codexis's capability to scale RNA production, potentially supporting future growth in RNA therapeutics. The deal's strategic importance may positively influence CDXS stock, especially if it leads to increased revenue or market share.
alphai scores every news story that mentions CDXS with an AI model for sentiment and relevance, and aggregates insider trades from CODEXIS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
U.S. stocks were mixed mid-session. Verizon (NYSE:VZ) reported Q2 adjusted EPS of $1.30 vs $1.27 consensus, with revenue of $34.25B missing the $35.11B estimate. GAAP EPS fell to 92 cents. Verizon raised full-year adjusted EPS guidance to $4.99-$5.04. Oil fell 4.3% to $88.26.
4 min readCODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,
2 min readCODEXIS, INC. (CDXS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001200375 0001200375 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17,
2 min readAnalysts have re-evaluated Codexis, Inc. (CDXS) after its latest quarterly results, which showed stronger-than-expected revenues of US$15m and lower losses per share at US$0.10. Despite an improved sentiment regarding future losses, the consensus price target has been reduced by 7.1% to US$6.58 due to ongoing profitability concerns and an anticipated revenue decline of 5.0% in 2026, contrasting with industry growth.
3 min readCodexis (NASDAQ: CDXS) has announced an agreement to manufacture 50 grams of small interfering RNA (siRNA) using its ECO Synthesis platform for a partner's preclinical cardiovascular program. This agreement demonstrates the platform's ability to produce material beyond early research volumes and serves as a potential pathway to further scale-up and commercial manufacturing. While no financial terms were disclosed, the deal highlights Codexis's ongoing efforts to commercialize its ECO Synthesis platform for larger-scale RNA therapeutics.
2 min readCodexis (CDXS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
3 min readREDWOOD CITY, Calif., Nov. 10, 2025 ( GLOBE NEWSWIRE ) -- Codexis, Inc. ( NASDAQ: CDXS ) , a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing ...
2 min readCodexis (CDXS) delivered earnings and revenue surprises of -46.67% and -53.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
2 min readAnnounces signing of $37.8m Supply Assurance Agreement with Merck ...
3 min readREDWOOD CITY, Calif., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Codexis, Inc. CDXS, a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference, being held September 3-5, ...
3 min read
